Dr Nick Holliday

Chief Scientific Officer

Nick Holliday has over 25 years’ experience in the molecular pharmacology of receptors and other drug targets, and in leading development of biochemical and cellular assay systems for analytical pharmacology and compound profiling.  His interests in imaging technologies to measure ligand binding and intracellular signalling have involved several collaborations with large pharma and SMEs over the years, most recently spearheading Excellerate’s participation in the EU funded SYNSTAR consortium to develop novel therapeutic approaches for obesity.  He also holds a part-time Associate Professorship at the University of Nottingham, and is a Fellow of the British Pharmacological Society.